Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma
Melanoma: Tumor differences within a patient may explain heterogeneous responses Patients with metastatic melanoma display molecular and immune differences across tumor sites associated with differential drug responses. A team led by Jennifer Wargo from the University of Texas MD Anderson Cancer Cen...
Guardado en:
Ejemplares similares
-
Identification of MicroRNA–mRNA Networks in Melanoma and Their Association with PD-1 Checkpoint Blockade Outcomes
por: Robert A. Szczepaniak Sloane, et al.
Publicado: (2021) -
Short-term treatment with multi-drug regimens combining BRAF/MEK-targeted therapy and immunotherapy results in durable responses in Braf-mutated melanoma
por: Michael G. White, et al.
Publicado: (2021) -
Spatially resolved analyses link genomic and immune diversity and reveal unfavorable neutrophil activation in melanoma
por: Akash Mitra, et al.
Publicado: (2020) -
Properties of double dowel joints constructed of Medium Density Fiberboard
por: Chen,Ming, et al.
Publicado: (2018) -
Engineering the Saccharomyces cerevisiae β-oxidation pathway to increase medium chain fatty acid production as potential biofuel.
por: Liwei Chen, et al.
Publicado: (2014)